stockrow4D Molecular Therapeutics, Inc.
FDMT Healthcare Biotechnology
4D Molecular Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.2 million, up 230,194.6% from fiscal 2024.
- Revenue
- +25,106.7%
- EPS
- −6.12%
- Free cash flow
- −61.3%
Quarter to June 2026, against a year earlier
Follow FDMT
Alert me
4D Molecular Therapeutics, Inc. (FDMT) EV/Sales
As of 6 November 2026, 4D Molecular Therapeutics, Inc. (FDMT) trades at a EV/Sales of 5.7×. Over the past ten years it has ranged from −10,857× (December 2024) to 6,149× (September 2024); the current reading is higher than 32% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.5× | — |
| FY2024 | −3,037× | — |
| FY2023 | 26.8× | (82.07%) |
| FY2022 | 149× | 617.29% |
| FY2021 | 20.8× | — |
| FY2020 | −0.7× | — |
| FY2019 | 9.7× | 0.00% |
| FY2018 | 9.7× | 0.00% |
| FY2017 | 9.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.4× | 123.14% |
| Mar 2026 | 2.9× | 461.17% |
| Dec 2025 | 0.5× | (99.97%) |
| Sep 2025 | 1,623× | — |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HELP Cybin Inc. compare | n/m |
| KURA Kura Oncology, Inc. compare | 1.7× |
| GERN Geron Corporation compare | 2.6× |
| WVE WAVE Life Sciences Ltd. compare | 3.6× |
| ZVRA Zevra Therapeutics, Inc. compare | 4.0× |
| FDMT 4D Molecular Therapeutics, Inc. | 5.7× |
| DBVT DBV Technologies S.A. compare | 211× |
| DSGN Design Therapeutics, Inc. compare | 1,919× |
| CADL Candel Therapeutics, Inc. compare | 3,940× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)